Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

The FDA has granted accelerated approval to Datroway for adults with previously-treated, locally advanced or metastatic EGFR-mutated NSCLC.

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...

FDA expands AstraZeneca's Datroway label, making it the first TROP2-directed lung cancer therapy approved in the United States.

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

The FDA has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo) for certain patients with locally-advanced or metastatic epidermal growth factor receptor (EGFR ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a subset of non-small cell lung ...

The US Food and Drug Administration (FDA) has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with locally advanced or metastatic epidermal growth factor ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non-small cell lung cancer, adding to its robust oncology portfolio. Despite ...